October 10, 2018 Mid-cap investors see Eastern promise in the third quarter Turbulence in Japan made the country’s biopharma industry a relatively safe haven – but clinical success or setbacks dictated the fortunes of most mid and small-cap players.
July 03, 2018 Shikeda masks slow second quarter for buyouts The money spent on biopharma acquisitions in the second quarter looks huge, but most of the total is down to one deal.
October 05, 2017 Back to the future for small caps, but not all benefit Oncology-focused smaller biotechs reap rich rewards, but generics groups face hard times.